Experienced in Hairy Cell Leukemia (HCL)

Dr. Julie R. Brahmer

Oncology

Johns Hopkins Medicine

Johns Hopkins University

301 Mason Lord Dr, Suite 1201,

Baltimore, MD

Accepting New Patients

Offers Telehealth

28 Years of Experience

Experienced in Hairy Cell Leukemia (HCL)

Johns Hopkins Medicine

Johns Hopkins University

301 Mason Lord Dr, Suite 1201,

Baltimore, MD

OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Julie Brahmer is an Oncologist in Baltimore, Maryland. Dr. Brahmer has been practicing medicine for over 28 years and is rated as an Experienced provider by MediFind in the treatment of Hairy Cell Leukemia (HCL). Her top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Lung Adenocarcinoma, and Small Cell Lung Cancer (SCLC). Dr. Brahmer is currently accepting new patients.

Her clinical research consists of co-authoring 226 peer reviewed articles and participating in 13 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has participated in 3 clinical trials in the study of Hairy Cell Leukemia (HCL).

Specialties

Oncology

Licenses

Internal Medicine in MD

Hospital Affiliations

Sibley Memorial Hospital

The Johns Hopkins Hospital

Johns Hopkins Bayview Medical Center

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance

Find your insuranceClose

Accepted insurance plans:

Aetna

Anthem

Blue Cross Blue Shield

Capital Blue Cross

INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
OTHER MEDICARE PART D
PPO

CareFirst

Change Healthcare

OTHER MEDICARE
OTHER MEDICARE PART D

Cigna

Health Care Services Corporation

HMO
INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
MEDICARE SNP
OTHER COMMERCIAL
OTHER MEDICARE
OTHER MEDICARE PART D
PPO

Highmark

Humana

HMO
INDEMNITY
POS
PPO

Johns Hopkins Healthcare

HMO
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE-MEDICAID PLAN

Medicaid

OTHER MEDICAID
STATE MEDICAID

UnitedHealthcare

Walgreens

MEDICARE DISCOUNT CARD
MEDICARE PDP
OTHER MEDICARE

Wellcare

EPO
HMO
INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
MEDICARE SNP
MEDICARE-MEDICAID PLAN
OTHER MEDICARE
OTHER MEDICARE PART D

View 10 Less Insurance Carriers -

Locations

JOHNS HOPKINS UNIVERSITY
301 Mason Lord Dr, Suite 1201, Baltimore, MD 21224

Call: 410-550-2339

Other Locations

JOHNS HOPKINS UNIVERSITY
600 N Wolfe St, Blalock 266, Baltimore, MD 21287

Call: 410-502-4340

JOHNS HOPKINS UNIVERSITY
5759 Cedar Ln, Columbia, MD 21044

Call: 443-718-3738

JOHNS HOPKINS UNIVERSITY
4940 Eastern Ave, Baltimore, MD 21224

Call: 410-550-0100

JOHNS HOPKINS UNIVERSITY
5755 Cedar Ln, Columbia, MD 21044

Call: 410-740-7544

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis

Enrollment Status: Active_not_recruiting

Publish Date: September 22, 2025

Intervention Type: Procedure, Drug, Biological

Study Drugs: Carboplatin, Pembrolizumab, Pemetrexed

Study Phase: Phase 3

DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

Enrollment Status: Active_not_recruiting

Publish Date: September 22, 2025

Intervention Type: Procedure, Biological

Study Drugs: Ipilimumab, Nivolumab

Study Phase: Phase 2

Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable Non-Small-Cell Lung Cancer.

Enrollment Status: Active_not_recruiting

Publish Date: August 15, 2025

Intervention Type: Drug

Study Drug: Nivolumab

Study Phase: Phase 2

A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)

Enrollment Status: Active_not_recruiting

Publish Date: May 21, 2025

Intervention Type: Other, Biological

Study Drugs: Ipilimumab, Nivolumab

Study Phase: Phase 3

Optimizing Immunosuppression for Steroid-Refractory Anti-PD-1/PD-L1 Pneumonitis

Enrollment Status: Terminated

Publish Date: June 13, 2024

Intervention Type: Drug, Biological

Study Drugs: Infliximab, Intravenous Immunoglobulin Therapy, Prednisone

Study Phase: Phase 2

Identifying Genetic Predictors of Durable Clinical Benefit to Pembrolizumab in Advanced Non-small Cell Lung Cancer (NSCLC) Alone and in Combination With Chemotherapy.

Enrollment Status: Terminated

Publish Date: July 24, 2023

Intervention Type: Drug

Study Drugs: Pembrolizumab, Carboplatin, Nab-paclitaxel, Pemetrexed

Study Phase: Phase 2

Ph1b/2 Open-Label,Multicenter Dose-Esc & Dose-Exp Study of Combo RMC4630 & Cobimetinib in Participants w/Relapsed/Refractory Solid Tumors & Ph1b Study of RMC4630 w/Osimertinib in Participants w/EGFR Mutation+,Locally Adv or Meta NSCLC